ReviewDrug discovery today2019
A human-on-a-chip approach to tackling rare diseases.
Review in Drug discovery today, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Development of a Multi-Organ Microphysiological (MPS) Model to Study Age-Related Comorbidities.Advanced biology · 2026Article
- Microgravity Therapy as Treatment for Decelerated Aging and Successful Longevity.International journal of molecular sciences · 2025Review
- Tissue chips as headway model and incitement technology.Synthetic and systems biotechnology · 2025Review
- Establishment of a Serum-Free Human iPSC-Derived Model of Peripheral Myelination.ACS biomaterials science & engineering · 2024Article
- Targeted Cancer Therapy-on-A-Chip.Advanced healthcare materials · 2024Review
- Implementation status of pharmacological studies in the development of orphan drugs.Orphanet journal of rare diseases · 2024Article
- Complex in vitro Model: A Transformative Model in Drug Development and Precision Medicine.Clinical and translational science · 2023Review
- Microphysiological systems as reliable drug discovery and evaluation tools: Evolution from innovation to maturity.Biomicrofluidics · 2023Review
- Building Blood Vessel Chips with Enhanced Physiological Relevance.Advanced materials technologies · 2023Article
- Literature Review on Health Emigration in Rare Diseases-A Machine Learning Perspective.International journal of environmental research and public health · 2023Review
- Optimization of Application-Driven Development ofTissue engineering. Part B, Reviews · 2022Review
- Artificial Intelligence in Medical Imaging and its Impact on the Rare Disease Community: Threats, Challenges and Opportunities.PET clinics · 2022Review
- Organ-on-a-chip platforms for accelerating the evaluation of nanomedicine.Bioactive materials · 2021Review
- High-Throughput Screening Platforms in the Discovery of Novel Drugs for Neurodegenerative Diseases.Bioengineering (Basel, Switzerland) · 2021Review
- Organ-on-a-Chip: A New Paradigm for Drug Development.Trends in pharmacological sciences · 2021Review
- Organ-on-a-Chip systems for new drugs development.ADMET & DMPK · 2021Review
- Tackling Current Biomedical Challenges With Frontier Biofabrication and Organ-On-A-Chip Technologies.Frontiers in bioengineering and biotechnology · 2021Review
- An Individual Patient's "Body" on Chips-How Organismoid Theory Can Translate Into Your Personal Precision Therapy Approach.Frontiers in medicine · 2021Article
- Fabrication of a hydroxyapatite-PDMS microfluidic chip for bone-related cell culture and drug screening.Bioactive materials · 2021Article
- Evolution of Biochip Technology: A Review from Lab-on-a-Chip to Organ-on-a-Chip.Micromachines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Drug development for rare diseases, classified as diseases with a prevalence of < 200 000 patients, is limited by the high cost of research and low target population. Owing to a lack of representative disease models, research has been challenging for orphan drugs. Human-on-a-chip (HoaC) technology, which models human tissues in interconnected in vitro microfluidic devices, has the potential to lower the cost of preclinical studies and increase the rate of drug approval by introducing human phenotypic models early in the drug discovery process. Advances in HoaC technology can drive a new approach to rare disease research and orphan drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.